Category

Healthcare

Daily Brief Health Care: Jeisys Medical, Akums Drugs and Pharmaceuticals, Samsung Biologics , Ainos and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Archimed Group Plans to Conduct a Second Tender Offer for Jeisys Medical
  • Akums Drugs and Pharmaceuticals Pre-IPO – Profitable but Needs to Scale up More
  • Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion
  • Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start


Archimed Group Plans to Conduct a Second Tender Offer for Jeisys Medical

By Douglas Kim

  • In the first tender offer, 42.5 million shares of Jeisys Medical were purchased by Archimed Group. Post tender offer, Archimed now owns an 82.1% stake in Jeisys Medical. 
  • On 24 July, it was announced that Archimed will be conducting a second tender offer for Jeisys Medical. The second tender offer will be made for 17.2% of common shares.
  • It could be difficult for Archimed to gain more than 95% stake at the end of the second tender offer. Rather, a third tender offer is likely in 2025.

Akums Drugs and Pharmaceuticals Pre-IPO – Profitable but Needs to Scale up More

By Ethan Aw

  • Akums Drugs and Pharmaceuticals (0200361D IN) is looking to raise up to US$239m in its upcoming India IPO. 
  • Akums Drugs and Pharmaceuticals (ADP) is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
  • In this note, we talk about the company’s historical performance.

Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion

By Tina Banerjee

  • In 2Q24, Samsung Biologics (207940 KS) reported 34% YoY revenue growth to KRW1,157B, driven by full utilization of Plants 1–3, ramp-up of Plant 4, milestone payment, and favorable Fx.
  • The company expects annual revenue to exceed KRW4T mark this year, thereby setting a record for the Korean pharmaceutical and biotechnology sector.
  • During 1H24, Samsung Biologics has secured order worth of KRW2.6T. Currently, the company is serving 16 out of the top 20 global pharmaceutical companies, up from 14 last year.

Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start

By Water Tower Research

  • Enrolled first subject in feline oral disease study, paving way for animal health opportunity.
  • The randomized, double- blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site.
  • Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: SAI Life Sciences, Arrowhead Pharmaceuticals , Telix Pharmaceuticals, TYK Medicines, BrainStorm Cell Therapeutics I, Lexaria Bioscience and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Sai Life Sciences Pre-IPO Tearsheet
  • Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!
  • Telix Pharmaceuticals (TLX AU): Fund Raising Via Convertible Debentures Amid Strong Business Outlook
  • Pre-IPO TYK Medicines (PHIP Updates) – Some Points Worth the Attention
  • BrainStorm Cell Therapeutics (BCLI) Update 23072024
  • LEXX: GLP-1 Agonist Program Updates


Sai Life Sciences Pre-IPO Tearsheet

By Sumeet Singh

  • SAI Life Sciences(SLS) is looking to raise up to US$500m in its upcoming India IPO. The deal will be run by Kotak, IIFL, Jefferies and MS.
  • SLS is a CRDMO. It provides end-to-end services across the drug discovery, development and manufacturing value chain, for small molecule NCE to global pharmaceutical innovators and biotechnology firms
  • As per Frost & Sullivan, SLS was the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from FY22 to FY24.

Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!

By Baptista Research

  • Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024.
  • A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities.
  • In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders.

Telix Pharmaceuticals (TLX AU): Fund Raising Via Convertible Debentures Amid Strong Business Outlook

By Tina Banerjee

  • Telix Pharmaceuticals (TLX AU) is raising A$600M via convertible debentures to fund key clinical development programs across the company’s therapeutic and diagnostic portfolio.
  • The convertible debentures, which are due to mature in 2029, will have annual yield between 2.00% and 2.75%. These will be listed on the Singapore Exchange.
  • Riding on strong performance during the first half, Telix has raised full-year 2024 revenue guidance by nearly 10% at mid-point to $490M–510M (A$745M–776M), representing 48–54% YoY growth.

Pre-IPO TYK Medicines (PHIP Updates) – Some Points Worth the Attention

By Xinyao (Criss) Wang

  • TY-9591 has differentiated indication compared with the current listed third-generation EGFR-TKI, but it still depends on the final clinical results, which also bring more uncertainty to the commercialization performance.
  • TYK’s development strategy requires it to invest heavily on head-to-head trials.Due to cash shortage, until TYK successfully addresses survival pressure,we recommend a more cautious assessment of pipeline prospects/future R&D arrangements.
  • TYK is a “mediocre” company. The valuation (RMB3.08 billion) is based on optimistic expectations that core product will be successfully developed, become Me-Better, and commercialized smoothly.We’re, however, conservative about this.

BrainStorm Cell Therapeutics (BCLI) Update 23072024

By ACF Equity Research

  • BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s).
  • Since initiation – CMC FDA questions resolved, commercialization team in place, raised US$ 4m (gross) enabling PIIIb rollout start, signed a CRO and lined up a commercial manufacturer, shortening the BLA timeline.
  • Whilst the US$ 4m raise and new warrants dilution effect has reduced our value range ~5%, it remains well above our >10x return investment hypothesis.

LEXX: GLP-1 Agonist Program Updates

By Zacks Small Cap Research

  • Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.
  • It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.
  • DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: SAI Life Sciences, Saint Bella, Oneness Biotech and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • SAI Life Sciences Pre-IPO Tear Sheet
  • Pre-IPO Saint Bella – The Outlook for Future Performance Growth Is Highly Uncertain
  • Oneness Biotech (4743 TT): Marketing Progress of Fespixon in China Opens a New Revenue Stream


SAI Life Sciences Pre-IPO Tear Sheet

By Tina Banerjee

  • SAI Life Sciences (SAILS12 IN) is planning to raise INR50B, consisting of INR8B worth of fresh issue and the rest will be OFS. 
  • Out of the proceeds from fresh issue, the company intends to utilize INR6B for repayment/pre-payment, in full or part, of all or certain outstanding borrowings availed by the company.
  • Sai Life Sciences is the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue as well as EBITDA CAGR during FY22–24.

Pre-IPO Saint Bella – The Outlook for Future Performance Growth Is Highly Uncertain

By Xinyao (Criss) Wang

  • SAINT BELLA’s revenue growth fluctuated because the pandemic led to the delay in the pregnancy plan of many families and an increase in the rate of abortion or miscarriage. 
  • The increasing contract liabilities indicate that short-term performance growth of SAINT BELLA is guaranteed, but the declining fertility rates in China will bring challenges to SAINT BELLA’s long-term growth momentum.
  • After Series B round financing in 2020, post-investment valuation was already about US$100 million. Valuation of SAINT BELLA should be higher than Aidigong Maternal & Child Health Limited (286 HK).

Oneness Biotech (4743 TT): Marketing Progress of Fespixon in China Opens a New Revenue Stream

By Tina Banerjee

  • Oneness Biotech (4743 TT) entered into an exclusive agreement with China Resources Dubl Crne Phrmctl (600062 CH) for commercialization of Fespixon in China, Hong Kong, and Macau.
  • Fespixon is approved in China as the first new drug for diabetic foot ulcer. Inclusion of the drug in NRDL is the next important milestone.
  • During 1H24, Oneness Biotech reported revenue of NT$57M, up 36% YoY. With expanding scale of operation, gross profit margin is improving (1Q24: 62.5% vs. 1Q23: 47.9%). Net loss is decreasing.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: China Traditional Chinese Medicine, Elpiscience Biopharmaceuticals and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Merger Arb Mondays (22 Jul) – China TCM, GA Pack, Huafa, Samson, CPMC, Fancl, Tatsuta, Capitol
  • Pre-IPO Elpiscience Biopharmaceuticals – Will Investors Still Buy in These Stories?



Pre-IPO Elpiscience Biopharmaceuticals – Will Investors Still Buy in These Stories?

By Xinyao (Criss) Wang

  • Elpiscience is incubated by LAV from the very beginning.The Company has strong capital operation capabilities, but the story of “founding team’s decent background + star cornerstone investors” doesn’t work anymore.
  • Elpiscience’s pipelines are still in early stage. However, investors are rational. They will no longer believe in those “good stories”, but focus more on cash flow and drug sales revenue.
  • Elpiscience’s business model has raised concerns about its future product sales scale and profits.The market may not recognize the post-investment valuation of US$599 million if check the valuation of peers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: InnoCare Pharma Ltd and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China Healthcare Weekly (July.21)-Rumor About Akeso, Takeover Bid for Legend Bio, InnoCare’s Trouble


China Healthcare Weekly (July.21)-Rumor About Akeso, Takeover Bid for Legend Bio, InnoCare’s Trouble

By Xinyao (Criss) Wang

  • There’re rumor that Akeso’s AK112 and AK104 2024 revenue is RMB300 million and RMB1.5-1.6 billion respectively. Sales of AK104 may be below expectations, so Akeso decided to enter NRDL reimbursement.
  • Regardless of whether there is a takeover offer, reasonable valuation of Legend Bio is between US$12.5bn-US$15bn based on solid fundamentals. This deal is “a test” for the management of Genscript.
  • Current stock price of InnoCare just reflects its essence. If no new catalysts (e.g. breakthroughs in clinical data, new licensing agreement, etc.), we are not optimistic about the prospects of InnoCare.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Cara Therapeutics, Intuitive Surgical, Aspira Women’s Health, Cocrystal Pharma , Longeveron and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? – Financial Forecasts
  • Intuitive Surgical (ISRG US): Beat-And-Raise 2Q24; Strong Procedure Growth; Solid Da Vinci 5 Rollout
  • Aspira Women’s Health, Inc. – Water Tower Hour Recap
  • COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated
  • LGVN: Alzheimer’s Drug on a Roll with FDA


Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? – Financial Forecasts

By Baptista Research

  • Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale.
  • Recent, Cara Therapeutics’ management announced a focus shift toward its most promising project, oral difelikefalin for treating notalgia paresthetica (NP), a chronic neuropathic condition with no currently approved therapies.
  • The reallocation of resources toward this program enables Cara Therapeutics to extend its cash runway into 2026, potentially covering all crucial value inflection milestones for the NP program.

Intuitive Surgical (ISRG US): Beat-And-Raise 2Q24; Strong Procedure Growth; Solid Da Vinci 5 Rollout

By Tina Banerjee

  • Intuitive Surgical (ISRG US) posted another strong quarterly result, with key performance indicators including total revenue, procedure growth, system placement, and EPS beating consensus.
  • 2Q24 procedure volume growth was 17% (estimate 15.5%) and accelerated from 16% in 1Q24. Intuitive narrowed full-year 2024 procedure growth forecast to 15.5–17.0%. The company raised gross margin guidance.
  • Despite phased rollout, 70 da Vinci 5 systems placement in 2Q24 seems impressive. It represents almost half of the total U.S. placement. In 2H24, placement is expected to increase modestly.

Aspira Women’s Health, Inc. – Water Tower Hour Recap

By Water Tower Research

  • OvaWatch mass monitoring completes OvaSuite portfolio.
  • With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass.
  • Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.

COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated

By Zacks Small Cap Research

  • On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company’s pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus.
  • The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg.
  • The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events.

LGVN: Alzheimer’s Drug on a Roll with FDA

By Zacks Small Cap Research

  • Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
  • The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Capitol Health, Grifols , Staar Surgical Co, Evotec AG, Medicus Pharma , Tonix Pharmaceuticals Holding and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Capitol Health (CAJ AU): Binding Merger with Integral Diagnostics (IDX AU)
  • Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): An Improved Image – Now Firmed
  • Liquid Universe of European Ordinary and Preferred Shares: July‘24 Report
  • STAAR Surgical Takeover Speculation: 4 Reasons Why We Are Optimistic! – Major Drivers
  • Evotec SE Potential Takeover: Does It Have What It Takes To Get Acquired? – Major Drivers
  • Medicus Pharma Ltd. – Medicus Submits Updated Phase 2 Clinical Protocol
  • TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis


Capitol Health (CAJ AU): Binding Merger with Integral Diagnostics (IDX AU)

By Arun George

  • Capitol Health (CAJ AU) has entered a binding merger proposal with Integral Diagnostics (IDX AU) at 0.12849 Integral shares per Capitol share.
  • The transaction will require approval from the ACCC and Capitol shareholders. Due to the minimal geographic overlap, ACCC clearance should be forthcoming.
  • The offer is attractive compared to historical exchange ratios, trading ranges and peer multiples. At the last close, the gross spread was 8.0%. 

Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): An Improved Image – Now Firmed

By David Blennerhassett

  • Back on the 17th June, diagnostic imaging provider Capitol Health (CAJ AU) announced it had entered into a process deed with Integral Diagnostics (IDX AU). Terms are now firmed.
  • IDX will issue 0.12849 new IDX shares for each Capitol share. Scrip terms are unchanged from that announced previously. Upon completing the transaction, Integral would hold 63% in the NewCo. 
  • Apart from ACCC signing off, this transaction looks priced to complete. 

Liquid Universe of European Ordinary and Preferred Shares: July‘24 Report

By Jesus Rodriguez Aguilar

  • Since mid-June, share-price spreads have generally tightened across our European liquid universe of ordinary and preferred shares (13 have tightened, 5 widened, 1 remained at same level).
  • Recommended trades long preferred / short ordinary shares: Atlas Copco, Grifols (see section on the company), Media-for-Europe, Sixt.
  • Recommended trades long ordinary / short preferred shares: Henkel, SSAB Svenska Stal.

STAAR Surgical Takeover Speculation: 4 Reasons Why We Are Optimistic! – Major Drivers

By Baptista Research

  • The first quarter of 2024 saw STAAR Surgical achieve a noteworthy result by generating net sales of $77.4 million, surpassing the expectations set for this period.
  • This result underscores the effectiveness of STAAR Surgical’s refined commercial strategy and the high uptake of its proprietary EVO ICL technology across all key geographical regions.
  • With a year-over-year increase represented by these figures, the company successfully navigated the challenges of a market predominantly inclined towards laser vision correction, where it successfully captured additional market share.

Evotec SE Potential Takeover: Does It Have What It Takes To Get Acquired? – Major Drivers

By Baptista Research

  • In assessing Evotec SE’s Q1 2024 fiscal results and its potential for acquisition, a reflection on both financial metrics and strategic initiatives offers insight.
  • Evotec SE, amidst a challenging market environment, reported a slight revenue decrease of 2% year-over-year, totaling EUR 208.8 million in Q1 2024.
  • The company’s primary revenue contraction stemmed from its Shared R&D business, which saw a decline of 23% compared to the same quarter in the previous year.

Medicus Pharma Ltd. – Medicus Submits Updated Phase 2 Clinical Protocol

By Zacks Small Cap Research

  • Medicus Pharma Ltd. (TSXV:MDCX) is focused on acquiring or partnering with life-science companies that are developing novel therapeutics for unmet healthcare needs that are already in the clinical trial stage.
  • Management plans fast-track these specific therapies through FDA clinical trials toward commercialization.
  • The company’s first acquisition was SkinJect, which has a novel, patented transdermal patch for the treatment of BCC.

TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis

By Zacks Small Cap Research

  • On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2024 and provided a business update.
  • Tonix will be filing a New Drug Application (NDA) for Tonyma (TNX-102 SL cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.
  • The company recently announced key findings from the initial phase of a market opportunity analysis for Tonmya by EVERSANA, including a high dissatisfaction rate with currently prescribed drugs for fibromyalgia patients, a high unmet need for effective therapies, and a high level of interest in Tonmya with an intended use of 40% among surveyed physicians.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Hygeia Healthcare Group, Longeveron , Distinct Healthcare Holdings and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Hong Kong: Stocks Facing the Passive Boot in August
  • LGVN: Alzheimer’s Drug on a Roll with FDA
  • Pre-IPO Distinct Healthcare Holdings-  Hard to Deliver the Expected Returns Due to Growth Bottleneck


Hong Kong: Stocks Facing the Passive Boot in August

By Brian Freitas

  • There are a bunch of stocks listed in Hong Kong that have underperformed the HSCEI INDEX and their peers and could be deleted from global passive portfolios in August.
  • The deletion from passive portfolios will lead to a liquidity event at the end of August where passive trackers will need to sell multiple days of ADV.
  • There has been a big jump in cumulative excess volume in some stocks and the A/H premium on a lot of the names has jumped over the last few months.

LGVN: Alzheimer’s Drug on a Roll with FDA

By Zacks Small Cap Research

  • Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
  • The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.

Pre-IPO Distinct Healthcare Holdings-  Hard to Deliver the Expected Returns Due to Growth Bottleneck

By Xinyao (Criss) Wang

  • Due to industry characteristics, it would be difficult for Distinct Healthcare to scale up. The Company is more of “a supplementary role” in the entire medical service system in China.
  • Profit margin is not satisfactory and cost side is also difficult to reduce. Even if Distinct Healthcare successfully turns losses into profits, it’s hard to generate good returns for investors.
  • Post-Money valuation was US$510 million after Series E financing. For a company that would encounter bottlenecks in both revenue and profit growth, it would be difficult to achieve high valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Glaukos Corp, Haemonetics Corp, Intuitive Surgical, Landos Biopharma , Revolution Medicines and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Glaukos Corporation: Is The Enhanced Training & Scaling of Surgeon Adoption Enough To Warrant A Bullish Rating? – Major Drivers
  • Haemonetics Corporation: A Tale Of Hospital Business Growth and Portfolio Expansion! – Major Drivers
  • Intuitive Surgical Inc.: New Product Innovations & The Strategy To Capitalize On Growth! – Major Drivers
  • Landos Biopharma Inc (LABP) – Tuesday, Apr 16, 2024
  • Revolution Medicines Inc.: Focus on Novel Combo-Therapeutic Approaches and Broader Genetic Mutations & Other Major Developments – Financial Forecasts


Glaukos Corporation: Is The Enhanced Training & Scaling of Surgeon Adoption Enough To Warrant A Bullish Rating? – Major Drivers

By Baptista Research

  • Glaukom Corporation has reported a promising start to Q1 2024, underscoring strong sales and a forward-looking strategy driven by innovations in glaucoma and corneal health technologies.
  • In the first quarter, Glaukom posted record net sales of $85.6 million, marking a 16% rise compared to the previous year.
  • U.S. and international glaucoma franchises each saw a year-over-year growth of 20%, showcasing robust market engagements driven mainly by the iStent products and the promising launch of iDose TR, a novel microinvasive injectable therapy.

Haemonetics Corporation: A Tale Of Hospital Business Growth and Portfolio Expansion! – Major Drivers

By Baptista Research

  • Haemonetics Corporation has demonstrated significant progress in its business strategies, leading to notable growth in its latest fiscal results, despite facing challenges and changes.
  • Noteworthy is the company’s bold shift in integrating service revenue within its commercial units and adjusting its reporting formats.
  • These efforts aim to streamline internal synergies and enhance accountability, potentially offering improved customer service and driving robust growth in the new work structure.

Intuitive Surgical Inc.: New Product Innovations & The Strategy To Capitalize On Growth! – Major Drivers

By Baptista Research

  • Intuitive Surgical’s first quarter of 2024 demonstrates robust performance in procedure growth and system placements despite some regional adversity.
  • The solid results reflect consistent execution and innovation in its product offerings, such as the launch of the next-generation multiport platform, da Vinci 5, and the roll-out of the da Vinci SP platform in Europe.
  • While the company shows resilience and growth potential, there are several factors and challenges that investors should consider when evaluating its investment prospects.

Landos Biopharma Inc (LABP) – Tuesday, Apr 16, 2024

By Value Investors Club

  • Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11
  • Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024
  • CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securities

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Revolution Medicines Inc.: Focus on Novel Combo-Therapeutic Approaches and Broader Genetic Mutations & Other Major Developments – Financial Forecasts

By Baptista Research

  • Revolution Medicines has posted the financial and operational updates for the first quarter of 2024, emphasizing significant advancements in its novel RAS(ON) inhibitor pipeline.
  • The company continues to prioritize advancing RMC-6236 into pivotal monotherapy trials in major cancers driven by oncogenic RAS variants, with a strong focus on expanding the clinical applications of RMC-6236 beyond G12X mutations into different RAS genotypes and tumor types.
  • In the past quarter, Revolution Medicines has provided encouraging preclinical and clinical data, particularly highlighting the potential of RMC-6236 in treating various cancers, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: China Traditional Chinese Medicine, Legend Biotech Corp, China Shineway Pharmaceutical, Hisamitsu Pharmaceutical Co, Sagility India, Avita Medical and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China Traditional Chinese Medicine (570 HK): Update Provides Fodder for Bulls and Bears
  • Legend Biotech (LEGN US): Takeover Interest – Possible but Tough to Pull Off
  • China Shineway Pharmaceutical (2877.HK) – Negative Growth in 24H1 Seems Inevitable
  • Hisamitsu Pharmaceutical (4530 JP): Mixed Performance in Q1FY25; No Change in FY25 Guidance
  • Sagility India Pre-IPO Tearsheet
  • Avita Medical Inc (RCEL) – Monday, Apr 15, 2024


China Traditional Chinese Medicine (570 HK): Update Provides Fodder for Bulls and Bears

By Arun George

  • China Traditional Chinese Medicine (570 HK)’s monthly update provides ammunition to both the bulls and bears. Since falling on no news on 26 June, the spread has widened to 31.8%. 
  • The bull view is that while the timelines are delayed, the privatisation remains on track as the update shows ongoing progress in satisfying the pre-condition. 
  • The bear view is that progress remains glacial, as the consortium wants to withdraw from a binding offer by failing to satisfy the pre-condition before the long stop date.

Legend Biotech (LEGN US): Takeover Interest – Possible but Tough to Pull Off

By Arun George

  • Legend Biotech Corp (LEGN US) shares increased 12% on Friday as a Street Insider report claimed it received takeover interest and hired Centerview Partners to help review the offer.
  • Genscript Biotech (1548 HK), the largest shareholder, shares rose 25%. Genscript responsded that it is not aware of any reasons for these share price movements and any inside information.
  • The chances for an offer are low as the offeror would face several hurdles. Nevertheless, without an offer, the upcoming CARVYKTI commercial production in 2H24 will support the share price.   

China Shineway Pharmaceutical (2877.HK) – Negative Growth in 24H1 Seems Inevitable

By Xinyao (Criss) Wang

  • Three business segments of Shineway showed negative YoY growth in 24Q1. 24Q2 performance could remain sluggish. We’re not optimistic about the 24H1 results due to the high base in 23H1.
  • It is expected that Shineway’s growth in 24H2 would pick up. If revenue growth of Shineway in 2024 full-year could be double-digit (e.g. 10-15% YoY), it is already good.
  • Shineway is undervalued. It has sufficient cash (cash balance of RMB5.9 billion by 2023) and is willing to distribute dividends (usually twice a year). Shineway is suitable for long-term holding.

Hisamitsu Pharmaceutical (4530 JP): Mixed Performance in Q1FY25; No Change in FY25 Guidance

By Tina Banerjee

  • Hisamitsu Pharmaceutical Co (4530 JP) has reported double-digit growth in revenue and net profit in Q1FY25. However, operating profit decreased 5% YoY due to higher expenses.  
  • Topline growth was mainly driven by Salonpas, which was named the world’s no. 1 OTC topical analgesic patch band for the eighth consecutive year.  
  • The company reiterated FY25 guidance of 7% revenue growth and low double-digit operating and net profit growth, as an increase in operating profit is expected for the full-year as planned.

Sagility India Pre-IPO Tearsheet

By Ethan Aw

  • Sagility India (2058883D IN) is looking to raise up to US$500m in its upcoming India IPO. The deal will be run by ICICI Securities, IIFL Securities, Jefferies and JP Morgan. 
  • Sagility India is a pure-play healthcare focused solutions and services provider to Payers (U.S. health insurance companies), and Providers (primarily hospitals, physicians, and diagnostic and medical devices companies). 
  • It supports the core business operations of both Payer and Provider clients. 

Avita Medical Inc (RCEL) – Monday, Apr 15, 2024

By Value Investors Club

  • AVITA Medical has a 75% market share in the burns market, surpassing competitors
  • The company’s recent financial performance has been strong, with an 84% increase in revenue in 2020
  • AVITA Medical has significant potential for growth and value creation in the future, given its position in the burns industry and growing market opportunity

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars